Arrowstreet Capital
ABUS icon

Arrowstreet Capital’s Arbutus Biopharma ABUS Stock Holding History

Arrowstreet Capital’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.12M Buy
+650,700
New +$2.86M ﹤0.01% 1426
2026
Q1 		– Sell
-35,116
Closed -$169K – 1817
2025
Q4 		$169K Sell
35,116
-124,002
-78% -$558K ﹤0.01% 1784
2025
Q3 		$722K Buy
+159,118
New +$584K ﹤0.01% 1650
2020
Q3 		– Sell
-62,321
Closed -$113K – 2297
2020
Q2 		$113K Buy
+62,321
New +$102K ﹤0.01% 2215

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arrowstreet Capital's ABUS Position: Q2 2026 in Review

Arrowstreet Capital opened a new position in Arbutus Biopharma (ABUS) in Q2 2026: 650,700 shares worth $3.12M. The stake represents ﹤0.01% of the portfolio and ranks #1426 among its holdings. This is a return to the name: Arrowstreet Capital previously reported a position in ABUS as recently as Q4 2025.

Arrowstreet Capital first reported a position in ABUS in Q2 2020 and has held it in 4 quarters since. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Arrowstreet Capital held 650,700 shares of Arbutus Biopharma worth $3.12M as of Q2 2026.
  • Arbutus Biopharma was a new Arrowstreet Capital position in Q2 2026.
  • Arbutus Biopharma made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1426 holding.
  • Arrowstreet Capital first reported a position in Arbutus Biopharma in Q2 2020 and has held it in 4 quarters since.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.